Market Intelligence, Clinical Progress, and High-Purity Reagents for ROS1 Fusion-Driven Oncology Development.
Target Overview
ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) is a key driver in non-small cell lung cancer (NSCLC) and other solid tumors. The canonical sequence (UniProt P08922) comprises three Fibronectin type-III domains (Fibronectin type-III 1, 2, 3) within the extracellular region. Known genetic variants include dbSNP:rs45606237, dbSNP:rs34245787, and dbSNP:rs1998206. In the clinic, acquired resistance mutations such as G2032R (solvent front), D2033N, and L2026M frequently emerge after first-line TKI therapy.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ROS1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | ROS1 ECD-Fc Fusion Protein (Human/Cyno orthologs, >95% purity, Sequence Verified, HEK293 Expressed, Endotoxin <1 EU/μg) | View ROS1 Products |
| Resistance Mutant | ROS1 G2032R Kinase Domain (Sequence Verified, >95% purity, active site integrity for SPR/DSF) | View ROS1 Products |
| Kinase Domain (WT & Mutant) | ROS1 Kinase Domain WT & G2032R/D2033N/L2026M proteins (>95% purity, Endotoxin <1 EU/μg) | View ROS1 Products |
| Gene Delivery (Full-Length) | ROS1 Lentivirus Premade Particles (Full-length ORF for stable cell lines, Puromycin selection) | View ROS1 Products |
| Gene Delivery (Fusion) | CD74-ROS1 Fusion Lentivirus (Native oncogenic fusion construct for pathological modeling) | View ROS1 Products |
| Benchmark Antibody | Anti-ROS1 Recombinant Antibody (Research grade, Endotoxin <1 EU/μg, Sequence Verified) | View ROS1 Products |
| Validation Tool | ROS1 siRNA Set (3 unique target sequences for knockdown verification) | View ROS1 Products |
| Related Target: ALK | Anaplastic Lymphoma Kinase (Closest homolog, 77% kinase domain identity, for selectivity counter-screening) | View ALK Products |
| Related Target: NTRK1 | Tropomyosin Receptor Kinase A (Essential for off-target toxicity profiling, e.g., entrectinib cross-reactivity) | View NTRK1 Products |
| Related Target: MET | Hepatocyte Growth Factor Receptor (Bypass resistance mechanism studies and combination therapy modeling) | View MET Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Solvent Front Mutation (G2032R) Screening | Comprehensive Mutant Panel (G2032R, D2033N, L2026M) available with >95% purity for SPR and DSF binding assays |
| Cross-Species Toxicity Evaluation (Cyno/Mouse) | Human/Cyno/Mouse ortholog proteins strictly verified by mass spec for preclinical safety profiling |
| Kinase Selectivity Counter-Screening | Homolog panel proteins (ALK, TRK) strictly verified by mass spec and sequence analysis |
| Fusion Partner Variability (CD74 vs SLC34A2) | Lentiviral constructs encoding native fusion junctions for physiologic expression patterns |
| Internalization Efficiency (ADC Development) | Full-length ROS1 lentivirus-generated stable cell lines preserving native conformation and endocytosis kinetics |
| CNS Penetration Modeling | BBB Transwell assays utilizing stable cell lines expressing ROS1 at physiologic surface density |
| Lack of Reliable Controls | Clinical Benchmark Antibodies and Reference TKIs included |
| False Positives in Cellular Assays | Validated ROS1 siRNA included for specificity checks |
Live ROS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic paradigm for ROS1 fusion-positive malignancies is shifting rapidly from first-generation inhibitors (e.g., crizotinib, entrectinib) to next-generation tyrosine kinase inhibitors (TKIs) engineered to overcome solvent front mutations and achieve central nervous system (CNS) penetrance. While crizotinib established proof-of-concept, the current R&D frontier is dominated by macrocyclic inhibitors such as repotrectinib, designed to sterically exclude G2032R resistance. The next wave of innovation targets antibody-drug conjugates (ADCs), bispecifics, and bifunctional degraders (PROTACs) to address acquired resistance beyond the kinase domain. As first-generation therapies induce resistance, the next wave of R&D is focusing on mutant-selective inhibitors and CNS-penetrant modalities for brain metastases. Major players including Pfizer, Roche, BMS/Turning Point, and early-stage biotechs are actively competing in this space.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Next-Gen TKI (Small Molecule) | Pfizer, Roche, BMS/Turning Point | NSCLC (including CNS metastases) | G2032R Mutant Protein for resistance profiling; Ba/F3 stable cell lines for IC50 determination |
| Pan-Kinase Inhibitor | Roche (Entrectinib) | Solid Tumors (NTRK/ROS1 fusion) | Cross-reactivity panel: ROS1 vs NTRK1 vs ALK recombinant kinases |
| ADC (Emerging) | AstraZeneca, Daiichi Sankyo (preclinical) | ROS1-positive solid tumors | Internalization Assay requiring full-length membrane protein (Lentivirus stable lines) |
| Bispecific (ROS1 x CD3) | Early-stage biotechs | Immunotherapy | Cell-based T-cell engagement assays using native conformation ROS1 cell lines |
| Targeted Protein Degrader (PROTAC) | Early-stage biotechs | TKI-Refractory NSCLC | Ternary Complex Validation (Need High-purity Intracellular Domains) |
Functional Domains and Key Mutations (Fact-Based)
Based on authoritative source (UniProt P08922), ROS1 contains three Fibronectin type-III domains in its extracellular region. Key documented genetic variants include rs45606237, rs34245787, and rs1998206. Resistance mutations commonly studied in clinical contexts include G2032R, D2033N, and L2026M (solvent front and gatekeeper residues).